Allera Health Products, Inc. is a research and development company dedicated to providing innovative, natural products that enhance the immune system. Headquartered in St. Petersburg, Florida, the biotechnology company was founded in 2005.
Allera holds the exclusive license for Proligna®, developed by scientists at the Tampa Bay Research Institute. ImmunExtra® is the first product based on this breakthrough compound; research continues to determine its true potential.
CHAIRMAN Frank Tufaro, Ph.D. is a former professor of microbiology and virology at the University of British Columbia. During his 17-year tenure, he published extensively in the areas of virology and cancer.
Frank was one of the original founders of Neurovir, Inc., a Vancouver-based biotech company with a mission to develop herpes-simplex virus oncolytic vectors for treating cancer. Frank initially served as Chief Scientific Officer, where he managed all aspects of drug development, including FDA interactions and contract manufacturing. He then served as CEO, during which time he negotiated and executed the successful merger of NeuroVir with MediGene AG, a public company headquartered in Munich, Germany.
Following the merger, Frank was appointed the Managing Director of the U.S. subsidiary of MediGene AG. In that capacity, he hired and led a team of 15 Directors and VPs, including representatives from manufacturing and process development, pre-clinical, QA/QC, regulatory, clinical, and business development. Within 18 months, he developed MediGene, Inc. into a fully integrated drug development company of 55 employees located in two facilities in San Diego.
From MediGene, Frank worked with several biotech start-up companies to develop successful financing and product development strategies.
Frank remains active in both the business and scientific arenas. He serves on the Scientific Advisory Boards of several public and private companies.